Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.53 USD
Change Today +0.005 / 0.96%
Volume 17.0K
EMIS On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

emisphere technologies inc (EMIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/26/15 - $0.90
52 Week Low
12/29/14 - $0.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

emisphere technologies inc (EMIS) Related Bloomberg News

View More Bloomberg News

emisphere technologies inc (EMIS) Related Businessweek News

No Related Businessweek News Found

emisphere technologies inc (EMIS) Details

Emisphere Technologies, Inc. operates as a commercial stage specialty pharmaceutical company in the United States. It offers Oral Eligen B12 Rx, an oral formulation medical food for use by B12 deficient individuals. The company is also developing GLP-1 (glucagon-like peptide-1), which is in Phase II clinical trial for the treatment for type 2 diabetes. Its preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. The company has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk’s insulin using the company’s Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is headquartered in Roseland, New Jersey.

10 Employees
Last Reported Date: 03/31/15
Founded in 1986

emisphere technologies inc (EMIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $650.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Vice President of Sales and Marketing
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2014.

emisphere technologies inc (EMIS) Key Developments

Emisphere Highlights Eligen Licensee Novo Nordisk's Entry into Phase 3A Development of Oral Semaglutide

Emisphere Technologies, Inc. highlighted that Eligen licensee Novo Nordisk A/S will initiate a global phase 3a development program with oral semaglutide, a once daily oral formulation of the long-acting GLP-1 analogue semaglutide, for the treatment of type 2 diabetes. Oral semaglutide is provided in a tablet formulation with an absorption-enhancing excipient, SNAC, which is one of Emisphere's Eligen Technology delivery agents, or 'carriers. Novo Nordisk announced its decision to initiate the PIONEER global phase 3a program consisting of seven trials and approximately 8,000 patients with type 2 diabetes. Novo Nordisk's decision to initiate this global phase 3a program follows encouraging results from the proof of concept phase 2 program and consultations with regulatory authorities. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Emisphere will be eligible to receive additional contingent product development and sales milestone payments and will also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Novo Nordisk is responsible for product development and commercialization under the terms of the Agreement.

Emisphere Technologies, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Emisphere Technologies, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue, net of discounts and allowances of $88,000. Operating loss was $4,564,000 compared to $1,539,000 a year ago. Net income before tax incentive was $7,136,000 compared to loss of $8,069,000 a year ago. Net income was $7,136,000 or $0.04 per diluted share compared to loss of $8,069,000 or $0.13 per diluted share a year ago. For the six months, the company reported revenue, net of discounts and allowances of $94,000. Operating loss was $9,232,000 compared to $3,884,000 a year ago. Net loss before tax incentive was $25,832,000 compared to $13,111,000 a year ago. Net loss was $25,832,000 or $0.43 per basic and diluted share compared to $11,427,000 or $0.19 per basic and diluted share a year ago.

Emisphere Technologies, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Emisphere Technologies, Inc. announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Aug 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EMIS:US $0.53 USD +0.005

EMIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.38 USD +0.62
Abeona Therapeutics Inc $4.31 USD +0.17
Boston Scientific Corp $16.92 USD +0.23
CR Bard Inc $193.09 USD +2.87
Medtronic PLC $71.13 USD +2.73
View Industry Companies

Industry Analysis


Industry Average

Valuation EMIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 338.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMISPHERE TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at